39 results about "Heparin Derivative" patented technology

A therapeutic composition is provided including a polysaccharide or a cationic peptide dissolved in an organic substance. The polysaccharide can be heparin or a derivative of heparin. The cationic peptide can be L-arginine, oligo-L-arginine or poly-L-arginine. The organic substance can be formamide. A method of coating an implantable medical device is also provided, comprising applying the therapeutic composition to the device and allowing the organic substance to evaporate. The device can be a stent.

The invention provides methods and compositions relating to the detection and neutralization of heparin and heparin derivatives in vivo and in vitro. To neutralize heparin in a patient sample, a composition comprising a complex of a heparin-binding agent and a carrier compound is used prior to performing coagulation assays.

The present invention provides compounds and methods for antagonizing the anticoagulant effect of an anticoagulant agent that is selected from UFH, LMWH, and a heparin/LMWH derivative in a patient comprising administering to the patient a compound of the invention or a salt thereof, or a composition comprising the same.

The invention discloses a kit for detecting antithrombase III (AT-III) in blood plasma by a developing substrate method. The kit comprises a heparin derivative, thrombin and a developing substrate reagent, wherein the heparin derivative is obtained by degrading heparin through heparinase II and cracking one or more unsaturated disaccharides from the heparin. The detection kit disclosed by the invention can avoid interference of a heparin cofactor II (HC-II) in a blood plasma sample, has the advantages of strong anti-interference capability, high flexibility, wide linear range, simplicity and rapidness in operation, strong instrument compatibility and the like, and has a wide application prospect.

The invention relates to a heparin derivative polysaccharide mixture and a preparation method and a medicinal composition thereof. Specifically, the heparin derivative polysaccharide mixture of the invention is a degradation product of heparin or heparin ester or heparin ester salt and is characterized in that the weight-average molecular weight is 3,100 to 4,500 Daltons, the activity of anti-coagulation factor Xa is high, and the activity of anti-coagulation factor IIa is low. The heparin derivative polysaccharide mixture of the invention has excellent antithrombotic performance, low side effect, and has no residues of adverse components such as organic base and dermatan sulfate and the like.

The invention discloses an anticancer medicament of heparin-taxol with low hemagglutinating resistance, which relates to a chemical bonding type anticancer medicament. The heparin-taxol medicament is prepared by heparin derivatives and taxol or taxol derivatives by the chemical bonding method, and the anticancer medicament not only has the blood-clot resistance lower than the heparin, but also has the anticancer property stronger than pure taxol medicaments.

The invention provides a method for selectively modifying a heparin structure by using biological enzyme, which can improve anticoagulation activity of heparin, reduce combination of heparin with blood protein such as platelet factors and the like, and reduce toxic and side effects. The invention belongs to the field of biological medicine. The antithrombus and anticoagulation activities of the heparin derivatives prepared by the method are 2 to 3 times higher than common heparin medicament, the 2-O-sulfate and 6-O-sulfate contents are about 20 percent of the common heparin, and the combination capability of the heparin derivatives with the platelet factors is about 20 percent of the common heparin. The novel heparin derivatives have high anticoagulation activity and low side effect.

The invention discloses a heparin derivative-poloxamer temperature sensitive hydrogel and a preparation method thereof. The poloxamer is used as a framework material, and N-Acetylated low molecular weight heparin and prednisone are compounded to obtain the hydrogel. The mass ratio of the N-Acetylated low molecular weight heparin to the poloxamer is 15-90:100-300. The preparation method comprises the following steps that step 1, the N-Acetylated low molecular weight heparin is weighed and placed in a serum bottle, and a PBS buffer solution is added; step 2, a prednisone drug PBS buffer solutionwith mass concentration of 5% is added, stirring at the room temperature is conducted and lasts for 12-36 hours; and step3, the poloxamer is weighed, and the solution in the step 2 is added, solutionstirring is conducted at 4-10 DEG C and last for 12-36 hours. The heparin derivative-poloxamer temperature sensitive hydrogel has the excellent effect, is long in antibacterial time, and has simple procedures; and industrialization can be achieved easily, and popularization and application are facilitated.

Method for obtaining and expanding postembryonic hematopoietic stem cells from umbilical cord blood while avoiding unwanted differentiation. Initial cells from umbilical cord blood are proliferated and multiplied ex vivo in a stroma-free medium and in the presence of a regio-modified glycan or glycosaminoglycan. The regio-modified glycan or glycosaminoglycan, e.g. a heparin derivative, is N-desulfated, and N-reacetylated or N-reacylated, in essence, on C2 atoms. The heparin derivative advantageously comprises less than 5 percent of C3-O-sulfate, at least 60 percent C2-O-sulfate, and it is preferably added in a quantity of 15 to 50 mg/L to the medium in order to stop an unwanted differentiation. The stem cells generated in this manner can differentiate, after expansion, into myeloma cells and lymphatic cells, and they can be used as an immunotherapeutic agent against many diseases.

The invention relates to an anticoagulation-resistant heparin derivative. The anti-Xa factor of the anticoagulation-resistant heparin derivative is lower than or equals to 70IU/mg, preferably the anti-Xa factor is lower than or equals to 60IU/mg, preferably is lower than or equals to 50IU/mg, preferably is lower than or equals to 40IU/mg, preferably is lower than or equals to 30IU/mg, preferably is lower than or equals to 20IU/mg, preferably is lower than or equals to 10IU/mg, the anti-IIa factor is lower than or equals to 175IU/mg, preferably is lower than or equals to 170IU/mg, preferably islower than or equals to 160IU/mg, preferably is lower than or equals to 150IU/mg, preferably is lower than or equals to 140IU/mg, preferably is lower than or equals to 130IU/mg, preferably is lower than or equals to 120IU/mg, preferably is lower than or equals to 110IU/mg, preferably is lower than or equals to 100IU/mg, preferably is lower than or equals to 90IU/mg, preferably is lower than or equals to 80IU/mg, preferably is lower than or equals to 70IU/mg, preferably is lower than or equals to 60IU/mg, preferably is lower than or equals to 50IU/mg, preferably is lower than or equals to 40IU/mg, preferably is lower than or equals to 30IU/mg, preferably is lower than or equals to 20IU/mg, and preferably is lower than or equals to 10IU/mg.

The invention provides a method for single-step terminal sterilization process for bio-active heparin coatings on materials and biomaterials containing heparin used in medical devices, such as catheters, tissue engineering scaffolds, or drug delivery carrier materials. This may include any medical device or implantable that could benefit from improved antithrombotic and biocompatible heparin surfaces. Other relevant device examples may include heparin or a heparin derivative coated stents to reduce clotting and restenosis, dental or ophthalmological implants. These materials may comprise additional polymeric compositions such as polyethyleneimine, dextran sulfate or their modified forms. These polymers together with heparin coatings may be applied to other substrate of medical devices such as metal, ceramics or biologically derived materials.

Polysaccharides, which are widely used as an anticoagulation drugs, especially heparin, are clinically administered only by intravenous or subcutaneous injection because of their strong hydrophilicity and high negative charge. Amphiphilic heparin derivatives were synthesized by conjugation to bile acids, sterols, and alkanoic acids, respectively. These heparin derivatives were slightly hydrophobic, exhibited good solubility in water, and have high anticoagulation activity. These slightly hydrophobic heparin derivatives are efficiently absorbed in the gastrointestinal tract and can be used in oral dosage forms. Methods of using these amphiphilic heparin derivatives and similarly modified macromolecules for oral administration are also disclosed.

The invention belongs to the field of prosthesis materials, and provides a keratoprosthesis optical center area. The keratoprosthesis optical center area is a surface-heparinized keratoprosthesis center material, and the surface-heparinized keratoprosthesis center material comprises a keratoprosthesis center material and a chemical modifier; the chemical modifier comprises a silane coupling agent and a heparin derivative or heparinoid derivative with anti-adhesion performance. According to the keratoprosthesis optical center area, the surface of polyvinyl alcohol hydrogel is chemically modified with the heparin derivative or the heparinoid derivative, and the excellent hydrophilia and high electronegativity of the heparin derivative or the heparinoid derivative are utilized, so that the keratoprosthesis center material with the surface provided with or containing the heparin derivative or the heparinoid derivative shows cell adhesive resistance. In addition, the keratoprosthesis optical center area is good in optical performance, water storage performance, swelling property and hydrophilic performance and high visible light transmittance.

The invention discloses a separation analysis method of derivatized heparin sulfate disaccharides containing free amino groups. The function relationship of the disaccharide quantity and mass spectrumdetection peak area can be used for quantitative determination of heparin and heparin sulfate disaccharide in practical biological samples. The separation analysis method can be used for detection ofheparin and heparin sulfate disaccharides, and especially heparin sulfate disaccharides containing free amino groups in liquid phase-mass spectrometry, and routine liquid chromatogram separating combined ultraviolet and fluorescent detector can be adopted in analysis. Important effect on clinical study on medical heparin, heparin sulfate, heparin derivatives, and disaccharides in various biological samples is achieved.

The invention relates to an anticoagulant coating composition. The composition is prepared by compounding functional polyether long-chain quaternary ammonium salt macromolecules and heparin or heparin derivatives. The invention further provides a preparation method of the anticoagulant coating composition. The preparation method comprises the following process steps: A, preparing a polymer precursor; B, preparing a functional polyether long-chain quaternary ammonium salt high polymer material; and C, preparing the anticoagulant coating composition, including a, preparing a functional polyether long-chain quaternary ammonium salt polymer solution, b, preparing a heparin sodium solution, and c, preparing the functional polyether long-chain quaternary ammonium salt polymer-heparin composition. The invention further provides application of the anticoagulant coating composition. The composition is applied to a base material or various instruments made of the base material. Compared with the prior art, the composition has the advantages that the performance is firmer and more stable, the anticoagulant effect is greatly prolonged, and polyethylene glycol molecules on the upper side chain of the composition can achieve the effects of buffering and protecting in the contact process of the base material and a blood coagulation matrix, so that the base material also has a lasting anticoagulant effect.